Last reviewed · How we verify
Docetaxel, Cisplatin, 5-FU and Cetuximab
Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor.
Docetaxel inhibits microtubule dynamics, Cisplatin induces DNA crosslinks, 5-FU inhibits thymidylate synthase, and Cetuximab binds to the epidermal growth factor receptor. Used for Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic breast cancer, Colorectal cancer, Head and neck cancer, Metastatic nasopharyngeal carcinoma.
At a glance
| Generic name | Docetaxel, Cisplatin, 5-FU and Cetuximab |
|---|---|
| Sponsor | Hong Kong Nasopharyngeal Cancer Study Group Limited |
| Drug class | Taxane, Platinum-based chemotherapeutic, Antimetabolite, Monoclonal antibody |
| Target | Microtubules, DNA, Thymidylate synthase, Epidermal growth factor receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Docetaxel works by stabilizing microtubules, preventing cell division, and ultimately leading to cell death. Cisplatin forms crosslinks in DNA, causing DNA damage and triggering cell death. 5-FU inhibits thymidylate synthase, an enzyme necessary for DNA synthesis, thereby preventing cancer cell growth. Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling pathways that promote cell proliferation.
Approved indications
- Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic breast cancer, Colorectal cancer, Head and neck cancer
- Metastatic nasopharyngeal carcinoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Rash
- Headache
Key clinical trials
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE2)
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases (PHASE3)
- AK129 Combination Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
- Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE2)
- Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer (PHASE2)
- Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial (NA)
- Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: